Last updated: February 15, 2026
What is MAXZIDE?
MAXZIDE is a combination medication containing hydrochlorothiazide (25 mg) and triamterene (37.5 mg). It is used to treat edema and hypertension by promoting diuresis and reducing fluid retention.
How is MAXZIDE positioned in the market?
MAXZIDE competes primarily with other fixed-dose diuretic combinations for hypertension and edema management. Its market presence depends on prescriber preference, patent status, and availability of generics.
What are the current sales figures for MAXZIDE?
In 2022, the U.S. sales of MAXZIDE (and similar combination diuretics) totaled approximately $170 million. The drug's sales volume has been relatively stable over the past five years, with minor fluctuations driven by generic competition and prescribing trends.
What are the key market drivers?
- Hypertension prevalence: An estimated 47% of U.S. adults have high blood pressure, creating consistent demand for antihypertensive drugs, including diuretics.
- Shift toward combination therapy: Increased adoption of fixed-dose combinations to improve adherence supports stable demand.
- Generic penetration: LOW. MAXZIDE remains under patent protection in some markets, limiting generic competition and maintaining higher pricing power.
What are the competitive challenges?
- Generic competition: Several generic hydrochlorothiazide/triamterene products have entered the market, exerting downward pressure on prices.
- Emerging therapies: New antihypertensive agents, such as SGLT2 inhibitors and mineralocorticoid receptor antagonists, influence prescribing patterns.
- Market saturation: The fixed-dose diuretic segment has achieved high penetration, leaving limited room for growth.
What are the sales projections for the next five years?
| Year |
Projected Sales (USD millions) |
Key Assumptions |
| 2023 |
$165 million |
Continued generic competition; stable demand |
| 2024 |
$160 million |
Slight decline as generic options increase; stable prescribing trends |
| 2025 |
$150 million |
Further generic penetration; minor price erosion |
| 2026 |
$140 million |
Growth in alternative therapies begins impacting sales |
| 2027 |
$130 million |
Market stabilization at lower levels due to competition |
This decline reflects ongoing generic entry and shifts toward newer antihypertensive medications.
What future market strategies could influence sales?
- Patent extensions: Securing patents on formulation or delivery methods may sustain higher prices temporarily.
- Brand differentiation: Marketing efforts emphasizing clinical benefits and safety profiles.
- Regulatory approvals: Expanding indications or formulations could create new revenue streams.
Summary
MAXZIDE remains a moderate market share product within the diuretic class. Its sales are expected to decline gradually over the next five years due to increasing generic competition and evolving treatment options. Strategic marketing and regulatory efforts may mitigate some decline but face structural market pressures.
Key Takeaways
- Current U.S. sales stand at approximately $170 million annually.
- The drug faces ongoing price erosion from generics despite patent protections.
- Market growth is limited by high penetration of fixed-dose diuretics and competition from newer antihypertensives.
- Sales projections suggest a decline from $165 million in 2023 to around $130 million in 2027.
- Competition and treatment paradigm shifts require adaptive strategies to maintain market relevance.
FAQs
1. What are the main competitors to MAXZIDE?
Generic hydrochlorothiazide/triamterene products and other combination drugs like Dyazide.
2. How does patent status affect MAXZIDE sales?
Patent expirations lead to increased generic competition, reducing prices and sales volume.
3. Are there any new formulations of MAXZIDE in development?
No publicly available new formulations are in late-stage development; market focus is on existing formulations and competing agents.
4. How do prescribing trends influence MAXZIDE's market share?
A shift towards newer antihypertensives may reduce the relative use of diuretics like MAXZIDE.
5. What regulatory challenges could impact MAXZIDE?
Changes in clinical guidelines favoring or discouraging specific drug classes could influence demand; patent disputes can also impact market stability.
Sources:
[1] IQVIA, "Prescription Drug Market Data," 2022.
[2] CDC, "High Blood Pressure Facts," 2022.
[3] FDA, "Drug Approvals & Patent Status," 2022.
[4] GlobalData, "Diuretic Market Analysis," 2022.
